Wellendorph P, Goodman M W, Burstein E S, Nash N R, Brann M R, Weiner D M
ACADIA Pharmaceuticals Inc., San Diego, CA 92121, USA.
Neuropharmacology. 2002 Jun;42(7):929-40. doi: 10.1016/s0028-3908(02)00041-2.
The pharmacology of histamine H(3) receptors suggests the presence of distinct receptor isoforms or subtypes. We herein describe multiple, functionally distinct, alternatively spliced isoforms of the human H(3) receptor. Combinatorial splicing at three different sites creates at least six distinct receptor isoforms, of which isoforms 1, 2, and 4, encode functional proteins. Detailed pharmacology on isoforms 1 (unspliced receptor), and 2 (which has an 80 amino acid deletion within the third intracellular loop of the protein) revealed that both isoforms displayed robust responses to a series of known H(3) agonists, while all agonists tested displayed increased potency at isoform 2 relative to isoform 1. Histamine, N(alpha)-methylhistamine, and R(-) and S(+)-alpha-methylhistamine are 16-23-fold more potent, while immepip and imetit are three to fivefold more potent. Antagonist experiments revealed a rank order of potency at both isoforms of clobenpropit>iodophenpropit>thioperamide, and these drugs are fivefold less potent at isoform 2 than isoform 1. To further explore the pharmacology of H(3) receptor function, we screened 150 clinically relevant neuropsychiatric drugs for H(3) receptor activity, and identified a small number of antipsychotics that possess significant antagonist activity.
组胺H(3)受体的药理学研究表明存在不同的受体亚型或异构体。我们在此描述了人H(3)受体的多种功能不同的可变剪接异构体。在三个不同位点的组合剪接产生了至少六种不同的受体异构体,其中异构体1、2和4编码功能性蛋白质。对异构体1(未剪接的受体)和异构体2(在蛋白质的第三个细胞内环内有80个氨基酸缺失)的详细药理学研究表明,这两种异构体对一系列已知的H(3)激动剂均表现出强烈反应,而所有测试的激动剂在异构体2上的效力相对于异构体1均有所增加。组胺、N(α)-甲基组胺以及R(-)和S(+)-α-甲基组胺的效力高16至23倍,而依美匹哌和碘替比妥的效力高3至5倍。拮抗剂实验表明,在两种异构体上,氯苯丙哌嗪>碘苯丙哌嗪>硫代哌啶的效力顺序相同,并且这些药物在异构体2上的效力比异构体1低5倍。为了进一步探究H(3)受体功能的药理学特性,我们筛选了150种临床相关的神经精神药物的H(3)受体活性,并鉴定出了少数具有显著拮抗剂活性的抗精神病药物。